Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DISTINCT: Nifedipine GITS and Candesartan in Hypertension
NCT01303783Phase 2Completed
- Sponsor
- Bayer
- Start
- Apr 2011
- Primary completion
- May 2012
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 13
01
Overview
Phase 2, randomised, double-blind trial of nifedipine GITS and candesartan cilexetil in essential hypertension (16 arms), sponsored by Bayer. Primary endpoint: Change from baseline in mean seated diastolic blood pressure at 8 weeks. Started Apr 2011; status: completed.
02
Drugs
nifedipine GITScandesartan cilexetil
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT01303783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01303783.